Inventor · disambiguated record
Everardo Cobos
Also filed as: COBOS EVERARDO
2 granted patents·6 pending applications·6 citations·filing 2009–2016
53Inventor score
Top patents by PatentIndex Score
8 records- 0181US9272014B2Galectin-3C combination therapy for human cancerCHIRIVA-INTERNATI MAURIZIO·Filed 2012·Granted Mar 1, 2016·5 cites·13 claims
- 0272US9744212B2Galectin-3C combination therapy for human cancerUNIV TEXAS TECH SYSTEM·Filed 2016·Granted Aug 29, 2017·1 cites·19 claims
- 0346US2010260787A1Human sperm fibrous sheath (FS) proteins: new target antigens for use in therapeutic cancer vaccines and diagnostic screening and Methods of Using SameKIROMIC INC·Filed 2009·Application pending·0 cites
- 0438US2016122408A1Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome InhibitorsUNIV TEXAS TECH SYSTEM·Filed 2016·Application pending·0 cites
- 0538US2017044223A1Human Sperm Fibrous Sheath (FS) Proteins: New Target Antigens For Use In Therapeutic Cancer Vaccines And Diagnostic Screening And Methods Of Using SameKIROMIC LLC·Filed 2016·Application pending·0 cites
- 0638US2016122407A1Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome InhibitorsUNIV TEXAS TECH SYSTEM·Filed 2016·Application pending·0 cites
- 0735US2015216931A1Galectin-3 inhibitor (gal-3m) is associated with additive anti-myeloma and anti-solid tumor effects, decreased osteoclastogenesis and organ protection when used in combination with proteasome inhibitorsUNIV TEXAS TECH SYSTEM·Filed 2015·Application pending·0 cites
- 0835US2015157691A1Galectin-3 to Treat Ovarian CancerUNIV TEXAS TECH SYSTEM·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Everardo Cobos files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →